Trial Profile
A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Antiphospholipid syndrome
- Focus Adverse reactions
- Acronyms TRAPS
- 30 Oct 2020 Results reporting the events during the two years follow up after the study closure published in the Journal of Thrombosis and Haemostasis
- 12 Jul 2018 Results published in the Blood.
- 27 Jan 2018 Status changed from recruiting to discontinued.